The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
Participants must not have any evidence of active Tuberculosis (TB).
Other protocol-defined Inclusion/Exclusion criteria apply.
Bristol-Myers Squibb
Lead sponsor